# FX-322 in Adults With Severe Sensorineural Hearing Loss

> **NCT04629664** · PHASE1 · COMPLETED · sponsor: **Frequency Therapeutics** · enrollment: 31 (actual)

## Conditions studied

- Hearing Loss, Sensorineural
- Noise Induced Hearing Loss
- Sudden Hearing Loss

## Interventions

- **DRUG:** FX-322
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04629664
- **Lead sponsor:** Frequency Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2021-05-26
- **Final completion:** 2021-09-20
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629664, "FX-322 in Adults With Severe Sensorineural Hearing Loss". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04629664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*